Published

Microdosing psychedelics: Motivations, subjective effects and harm reduction.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: The International journal on drug policy
Date: 2020-01-01
Source: PubMed
DOI: 10.1016/j.drugpo.2019.11.008
PubMed: 31778967

Authors

Lea T Amada N Jungaberle H Schecke H Klein M

Watch author

Derived topics and classifications

psilocybin Depression Anxiety Microdosing Wellbeing Clinical Trial Randomized Controlled Trial Observational Study Randomized Controlled Trial

Citation graph

0 referenced DOIs found in stored source metadata. 4 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats2026-10-01 Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults2026-10-01 The subtle science: a systematic review of psilocybin magic mushroom and truffle microdosing2026-08-19 Psilocybin and Mental Health Outcomes: Scoping Review with ☸️SAIMSARA2026-06-15

Related papers

Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.Trials · 2024-05-21 S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-19 Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression.Trials · 2024-07-03 A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 A One-Year Observational Follow-up Study of Participants With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-ControlClinicalTrials.gov · 2026-05-04 A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive DisorderClinicalTrials.gov · 2025-08-19 Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)ClinicalTrials.gov · 2025-05-28